Page last updated: 2024-08-21

pyrazines and Opportunistic Infections

pyrazines has been researched along with Opportunistic Infections in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (28.57)29.6817
2010's5 (71.43)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Alinari, L; Bond, DA; Maddocks, K1
Morrison, VA1
Grünberg, K; Sonneveld, P; Wittgen, BP; Wondergem, MJ; Zweegman, S1
Bahlis, NJ; Barr, PM; Cooper, BW; Dowlati, A; Fu, P; Gerson, SL; Horvath, N; Koc, ON; Lazarus, HM; Snell, MR1
Cantaffa, R; Carillio, G; Kropp, M; Lamberti, AG; Molica, S; Piro, E1
Bostrom, BC; Eckroth, E; Gaynon, PS; Malvar, J; Messinger, YH; Sposto, R; van der Giessen, J1
Hashimoto, N; Okamoto, S; Sadahira, K; Tsukada, Y; Ueda, T; Yokoyama, K1

Reviews

2 review(s) available for pyrazines and Opportunistic Infections

ArticleYear
Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma: review of current evidence and future directions.
    Clinical advances in hematology & oncology : H&O, 2019, Volume: 17, Issue:4

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cardiovascular Diseases; Clinical Trials as Topic; Forecasting; Gastrointestinal Neoplasms; Hemorrhage; Humans; Immunologic Factors; Lymphocytosis; Lymphoma, Mantle-Cell; Molecular Targeted Therapy; Neoplasm Proteins; Opportunistic Infections; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Salvage Therapy

2019
Immunosuppression associated with novel chemotherapy agents and monoclonal antibodies.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014, Nov-15, Volume: 59 Suppl 5

    Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents; Bacterial Infections; Boronic Acids; Bortezomib; Female; Humans; Immune Tolerance; Male; Middle Aged; Mycoses; Neoplasms; Opportunistic Infections; Pyrazines; Tumor Necrosis Factor-alpha; Virus Diseases

2014

Trials

2 trial(s) available for pyrazines and Opportunistic Infections

ArticleYear
Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma.
    British journal of haematology, 2009, Volume: 147, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Nervous System Diseases; Neutropenia; Opportunistic Infections; Pyrazines; Rituximab; Thrombocytopenia; Treatment Outcome; Vidarabine

2009
Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.
    Blood, 2012, Jul-12, Volume: 120, Issue:2

    Topics: Adolescent; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bacterial Infections; Boronic Acids; Bortezomib; Child; Child, Preschool; Dexamethasone; Doxorubicin; Female; Humans; Infant; Kaplan-Meier Estimate; Male; Opportunistic Infections; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Recurrence; Remission Induction; Treatment Outcome; Vincristine; Young Adult

2012

Other Studies

3 other study(ies) available for pyrazines and Opportunistic Infections

ArticleYear
Interstitial pneumonitis caused by Pneumocystis jirovecii pneumonia (PCP) during bortezomib treatment.
    Histopathology, 2009, Volume: 54, Issue:5

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Multiple Myeloma; Opportunistic Infections; Pneumocystis carinii; Pneumonia, Pneumocystis; Pyrazines

2009
Visceral leishmaniasis infection in a refractory multiple myeloma patient treated with bortezomib.
    Annals of hematology, 2012, Volume: 91, Issue:11

    Topics: Antineoplastic Agents; Antiprotozoal Agents; Bone Marrow Cells; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Humans; Immunosuppressive Agents; Italy; Leishmania donovani; Leishmaniasis, Visceral; Male; Middle Aged; Multiple Myeloma; Opportunistic Infections; Proteasome Inhibitors; Pyrazines; Treatment Outcome

2012
Itraconazole may increase the risk of early-onset bortezomib-induced peripheral neuropathy.
    International journal of hematology, 2012, Volume: 96, Issue:6

    Topics: Adult; Aged; Antifungal Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Cytochrome P-450 Enzyme System; Dexamethasone; Diabetes Complications; Drug Synergism; Female; Humans; Inactivation, Metabolic; Incidence; Itraconazole; Male; Middle Aged; Multiple Myeloma; Mycoses; Opportunistic Infections; Peripheral Blood Stem Cell Transplantation; Peripheral Nervous System Diseases; Protease Inhibitors; Proton Pump Inhibitors; Pyrazines; Retrospective Studies; Risk Factors; Salvage Therapy

2012